Suraksha Diagnostic Limited , a leading player in the diagnostic services sector, has announced its consolidated financial results for the quarter and six months ended September 30, 2025, showcasing a remarkable improvement in performance.

Revenue Growth

The company reported a significant increase in revenue for Q2, with consolidated revenue from operations rising to ₹7,258.63 lakhs, up from ₹6,675.35 lakhs in the previous quarter. This represents a quarter-on-quarter growth of approximately 8.7%.

Profit Surge

Suraksha Diagnostic experienced a substantial increase in profitability. The consolidated profit after tax for Q2 surged to ₹892.37 lakhs, compared to ₹95.48 lakhs in the prior quarter, marking an impressive growth of about 936%.

Financial Highlights

Six-Month Performance

For the six-month period ended September 30, 2025, Suraksha Diagnostic reported consolidated revenue of ₹12,748.50 lakhs with a profit after tax of ₹1,828.28 lakhs, demonstrating strong overall performance for the first half of the fiscal year.

Key Developments

• The company completed the acquisition of Fetomat Wellness Private Limited on April 8, 2025, acquiring a 63% equity stake for ₹3,73,423 equity shares, making it a subsidiary.
• Basic earnings per share improved significantly to ₹1.72 for the quarter from ₹0.18 in the previous quarter.

Board Meeting and Approval

The Board of Directors met on November 10, 2025, where these unaudited financial results were approved.

The results indicate that Suraksha Diagnostic is experiencing substantial growth in both its top line and bottom line. The dramatic increase in profitability is particularly noteworthy and may suggest successful cost management strategies or higher-margin service offerings.

Suraksha Diagnostic Limited, a prominent player in the diagnostic services sector, has reported another significant insider transaction. Dr. Somnath Chatterjee, the company's Promoter, Chairman, and Joint Managing Director, has further increased his stake in the firm through an open market purchase.

Transaction Details

Dr. Chatterjee acquired an additional 7,800 equity shares of Suraksha Diagnostic Limited through the open market. This strategic move has resulted in a notable change in his shareholding position:

The transaction has increased Dr. Chatterjee's ownership by 0.015% of the company's total equity.

Company Overview

Suraksha Diagnostic Limited has a paid-up capital of ₹10,41,61,516, consisting of 5,20,80,758 equity shares with a face value of ₹2 each.

Regulatory Compliance

In compliance with regulatory requirements, Dr. Chatterjee promptly disclosed the transaction details to the stock exchanges. The disclosure ensures transparency and adherence to regulatory standards.

Implications

This additional acquisition by a key insider, following a previous purchase, may be viewed positively by the market, as it potentially signals continued confidence in the company's future prospects. However, investors are advised to conduct their own research and consider various factors before making investment decisions.

Suraksha Diagnostic Limited continues to operate in the competitive healthcare diagnostics sector, with this latest development highlighting ongoing interest from its leadership in strengthening their position within the company.